Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS Inc (DE:135A)
:135A
135A Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.93 - €2.50
Previous CloseN/A
Volume0.00
Average Volume (3M)88.00
Market Cap
€38.60M
Enterprise Value€19.08M
Total Cash (Recent Filing)$11.44M
Total Debt (Recent Filing)$15.08M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Mar 26, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,948,990
10 Day Avg. Volume238
30 Day Avg. Volume88
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.74
Price to Cash Flow (P/CF)13.30
P/FCF Ratio13.30
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.15
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
€7.60Price Target Upside692.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
SCYNEXIS News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceScynexis remains well-capitalized, with a strong balance sheet which should provide sufficient runway into 3Q26, and potentially extended by ongoing activity with GSK.
Licensing And CommercializationThe drug Ibrexafungerp is cidal versus static, enhancing its efficacy, and has been licensed to GlaxoSmithKline for commercialization.
Treatment SuccessThe Phase 3 FURI data for Ibrexafungerp showed a 60.9% treatment success rate, which is consistent with interim data and a very good result in this setting.
Bears Say
---
Options Prices
Currently, No data available
---
Ownership Overview
4.64% Insiders
24.19% Mutual Funds
13.54% Other Institutional Investors
52.78% Public Companies and Individual Investors
135A FAQ
What was SCYNEXIS Inc’s price range in the past 12 months?
SCYNEXIS Inc lowest stock price was €0.93 and its highest was €2.50 in the past 12 months.
What is SCYNEXIS Inc’s market cap?
SCYNEXIS Inc’s market cap is €38.60M.
When is SCYNEXIS Inc’s upcoming earnings report date?
SCYNEXIS Inc’s upcoming earnings report date is Mar 26, 2025 which is in 24 days.
How were SCYNEXIS Inc’s earnings last quarter?
SCYNEXIS Inc released its earnings results on Nov 06, 2024. The company reported -€0.057 earnings per share for the quarter, beating the consensus estimate of -€0.136 by €0.079.
Is SCYNEXIS Inc overvalued?
According to Wall Street analysts SCYNEXIS Inc’s price is currently Undervalued.
Does SCYNEXIS Inc pay dividends?
SCYNEXIS Inc does not currently pay dividends.
What is SCYNEXIS Inc’s EPS estimate?
SCYNEXIS Inc’s EPS estimate is -0.02.
How many shares outstanding does SCYNEXIS Inc have?
SCYNEXIS Inc has 37,948,990 shares outstanding.
What happened to SCYNEXIS Inc’s price movement after its last earnings report?
SCYNEXIS Inc reported an EPS of -€0.057 in its last earnings report, beating expectations of -€0.136. Following the earnings report the stock price went down -2.585%.
Which hedge fund is a major shareholder of SCYNEXIS Inc?
Currently, no hedge funds are holding shares in DE:135A
---
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.60 (692.16% Upside)
€7.60 (692.16% Upside)
Blogger Sentiment
Bullish
DE:135A Sentiment 70%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.41%
12-Months-Change
Fundamentals
Return on Equity
-48.42%
Trailing 12-Months
Asset Growth
-33.33%
Trailing 12-Months
Company Description
SCYNEXIS Inc
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
---
135A Stock 12 Month Forecast
Average Price Target
€7.60
▲(692.16% Upside)
Technical Analysis
Cara Therapeutics
―
XTL Biopharmaceuticals Ltd. Sponsored ADR
―
VistaGen Therapeutics
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Best Analysts Covering 135A
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-36.32%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -36.32% per trade.
---